Shots:

• The company reported the results from the P-IIIa STEP 1 trial of the STEP programme assessing semaglutide (2.4 mg- SC- qw) vs PBO in adults with obesity for 68 wks. The results will be presented at ECO 2021
• Results: The therapy showed 14.9% weight loss- 43.8% improvement in total weight-related QoL scores- 51.2% vs 32.9% participants improved weight-related physical function- 40% vs 27% participants achieved improvement in health-related physical functioning score- improved psychological well being
• Semaglutide is an analogue of the human GLP-1 hormone- currently under investigation for chronic weight management and is under FDA and EMA’s review

  Ref: PRNewswire | Image: Novo Nordisk